Discussion on the Current Situation and Price of Domestic Drugs Eltrombopag/Eltrombopag

Eltrombopag/Eltrombopag This oral thrombopoietin receptor agonist has gradually become an important drug in the treatment of thrombocytopenia. Whether it is chronic immune thrombocytopenia (ITP), chronic hepatitis C or aplastic anemia, eltrombopag can inhibit bone marrow stem cells and increase platelet production through its unique mechanism, thereby increasing the patient's platelet count and significantly reducing or eliminating the risk of bleeding. Although eltrombopag is not a cure for these conditions, it improves symptom management for many patients by increasing platelet counts.

In terms of domestic drugs, after strict review by the State Food and Drug Administration, four pharmaceutical companies have successfully developed and approved eltrombopag ethanolamine tablets for sale, namely Jiangsu Aosaikang Pharmaceutical, Zhengda Tianqing Pharmaceutical, Qilu Pharmaceutical and Sichuan Kelun Pharmaceutical. At present, the specific price information of these domestically produced eltrombopag has not been released. The emergence of domestically produced drugs has also provided patients with more medication options.

Eltrombopag’s original drug is relatively expensive in China. The price of original drugs of different specifications ranges from RMB 2,000 to RMB 4,000, which is undoubtedly a considerable financial burden for many patients. Fortunately, this drug has been included in the scope of medical insurance reimbursement, which means that patients who meet the indications can enjoy the medical insurance reimbursement policy when purchasing the drug, thus reducing financial pressure.

In the international market, the price of Eltrombopag is also high. Although in places such as Turkey and India, the price of the original drug may be slightly lower, about more than 1,000 yuan per box (the price may fluctuate due to exchange rates), it is still a considerable expense for most patients.